Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Psoralen derivatives as inhibitors of mycobacterium tuberculosis proteasome
ID
Rožman, Kaja
(
Author
),
ID
Alexander, Evan M.
(
Author
),
ID
Ogorevc, Eva
(
Author
),
ID
Bozovičar, Krištof
(
Author
),
ID
Sosič, Izidor
(
Author
),
ID
Aldrich, Courtney C.
(
Author
),
ID
Gobec, Stanislav
(
Author
)
PDF - Presentation file,
Download
(6,28 MB)
MD5: A0CF9586CFB79249DCD04C788F7D6B3E
URL - Source URL, Visit
https://www.mdpi.com/1420-3049/25/6/1305
Image galllery
Abstract
Protein degradation is a fundamental process in all living organisms. An important part of this system is a multisubunit, barrel-shaped protease complex called the proteasome. This enzyme is directly responsible for the proteolysis of ubiquitin- or pup-tagged proteins to smaller peptides. In this study, we present a series of 92 psoralen derivatives, of which 15 displayed inhibitory potency against the Mycobacterium tuberculosis proteasome in low micromolar concentrations. The best inhibitors, i.e., 8, 11, 13 and 15, exhibited a mixed type of inhibition and overall good inhibitory potency in biochemical assays. N-(cyanomethyl)acetamide 8 (K$_i$ = 5.6 µM) and carboxaldehyde-based derivative 15 (K$_i$ = 14.9 µM) were shown to be reversible inhibitors of the enzyme. On the other hand, pyrrolidine-2,5-dione esters 11 and 13 irreversibly inhibited the enzyme with K$_i$ values of 4.2 µM and 1.1 µM, respectively. In addition, we showed that an established immunoproteasome inhibitor, PR-957, is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (K$_i$ = 5.2 ± 1.9 µM, k$_{inact}$/K$_i$ = 96 ± 41 M$^{−1}$·s$^{−1}$). These compounds represent interesting hit compounds for further optimization in the development of new drugs for the treatment of tuberculosis.
Language:
English
Keywords:
protein degradation
,
proteasome
,
Mycobacterium tuberculosis
,
psoralens
,
nonpeptidic proteasome inhibitors
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
FFA - Faculty of Pharmacy
Publication status:
Published
Publication version:
Version of Record
Year:
2020
Number of pages:
14 str.
Numbering:
Vol. 25, iss. 6, art. 1305
PID:
20.500.12556/RUL-133422
UDC:
547.96.057:615.4
ISSN on article:
1420-3049
DOI:
10.3390/molecules25061305
COBISS.SI-ID:
4894321
Publication date in RUL:
26.11.2021
Views:
831
Downloads:
176
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Molecules
Shortened title:
Molecules
Publisher:
MDPI
ISSN:
1420-3049
COBISS.SI-ID:
18462981
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:
12.03.2020
Secondary language
Language:
Slovenian
Keywords:
sinteza beljakovin
,
zaviralci Mycobacterium tuberculosis
,
imunoproteasom
,
farmacevtska kemija
,
beljakovine
Projects
Funder:
ARRS - Slovenian Research Agency
Project number:
P1-0208
Name:
Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin
Funder:
Other - Other funder or multiple funders
Funding programme:
Republic of Slovenia, Ministry of Education, Science and Sports
Project number:
C3330-17-529028
Funder:
Other - Other funder or multiple funders
Funding programme:
Republic of Slovenia, Ministry of Education, Science and Sports
Project number:
Raziskovalci-2.0-UL-FFA-529028
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back